DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Martin M, Holmes FA, Ejlertsen B. et al
ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol 2017;
18 (12) 1688-1700
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.